Advertisement

Topics

Shire's oncology exit weighs on potential Takeda bid

04:46 EDT 16 Apr 2018 | BioPharmaDive

Analysts expect a $2.4 billion deal with Servier to give Shire more negotiating power with Takeda, but it likely won't keep the suitor at bay.

Original Article: Shire's oncology exit weighs on potential Takeda bid

NEXT ARTICLE

More From BioPortfolio on "Shire's oncology exit weighs on potential Takeda bid"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...